“showed a trend”

Muscle wet‐weight ratios showed a trend of improvement, with a significant increase in quadriceps wet weight in the PV‐cre group (Unpaired t ‐test, t 6 = 2.818, p = 0.030; Figure 4a–d ).

Between-group comparisons showed a trend toward a greater IOP decrease on POD 1 (p=0.03), but not POM 3 (p=0.81).

In the under-5 age group, the SMA 3a group also showed a trend towards increasing score at and after 12 months, although this was only significant at 6 months in both the RHS and HFMSE (median 6 ( p = 0.03) and 3 ( p = 0.06), respectively).

In our study, weight loss (52.8%) and cough (59.0%) were the two most common presenting complaints that showed a trend towards a decreased survival (p = 0.03) in patients with ESSCLC.

An analysis comparing PFS by first-line therapy choice across KRAS variants showed a trend toward improved PFS with first-line fluorouracil-based therapy versus gemcitabine-based therapy for G12R (12.17 v 9.9 months; HR, 1.73 [95% CI, 1.05 to 2.84]; P = .0305) and the opposite trend with reduced PFS with first-line fluorouracil-based therapy for Q61 (3.13 v 5.6 months; HR, 0.46 [95% CI, 0.21 to 0.99]; P = .0479; Data Supplement, Table S2).

Adjusted linear regression showed a trend for an association between longer DD and a greater sNfL z -score ( B = 0.35; p = 0.031; adjusted p [5] = 0.16); however, Spearman’s correlation was not significant (rho = 0.18; p = 0.078; n = 98) ( Figures 2 – 4 ).

Infants of SCZ mothers showed a trend towards less attentiveness ( p = 0.032) compared to the infants of MDD mothers.

However, participants with GG genotypes showed a trend toward better performance in the visuospatial function compared with the AA + AG genotypes ( p = 0.032).

13.5% in Q1, p < 0.001), and alcohol consumption patterns showed a trend towards higher consumption in the lower LDL/HDL ratio groups ( p = 0.032).

In addition, the SDNN values showed a trend of a decrease followed by an increase in the pre- and post-tests, and the differences in the changes were significant ( F = 13.078, p = 0.032, ɳp 2 = 0.231).

Serum albumin showed a trend toward a protective effect (HR = 0.82, 95% CI: 0.68–0.98, p = 0.033).

Conversely, in the thalamus, while preclinical scrapie-affected animals showed a trend towards upregulation of SPP1 , a significant upregulation ( p -value = 0.033) was evident in the clinical stage of the disease, compared to healthy controls.

Higher APACHE II score showed a trend toward increased mortality, while vasopressor use within the first 24 h was associated with increased mortality risk (HR 0.47; 95% CI 0.24–0.94; p = 0.033).

However, the Mann–Whitney U test comparing the biceps brachii group and the brachialis plus brachioradialis group on pronator teres toxin dose showed a trend towards significance ( p = 0.033, adjusted alpha = 0.0167), suggesting that patients in the biceps brachii group tended to receive a higher dose of pronator teres toxin.

Concerning the type of infection, patients showed a trend towards a higher rate of nosocomial infections when sTREM-1 plasma concentrations at V1 were above 532 pg/mL ( p = 0.033), whereas there was no statistical difference when the cut-off of 400 pg/mL was used ( p = 0.154).

Participants with hypoxic burden ≥42%min·h −1 showed a trend towards higher likelihood of significant decline in phonemic fluency (OR 2.26, p=0.033, according to Model 3) ( supplementary tables S10 and S11 ).

The median OS (14.17 months) was significantly superior to that of the Control group (8.88 months, P < 0.001) and showed a trend towards prolongation compared to the IP-Cis group (11.23 months, P = 0.033).

In the subgroup study, we demonstrated that compared with RASi, the use of ARNI showed a trend toward reducing the incidence of cardiovascular events, with a statistically significant difference between the two groups (HR 2.811, 95%CI 1.063 − 7.434, p = 0.033), which was consistent with previous research findings.

The DMN and VAN also showed a trend of increased IntraNC (DMN: p = .033; VAN: p = .011), but these results failed to reach significance once corrected for multiple comparisons.

Overall survival showed a trend toward worse prognosis in patients with germline mutations ( P =0.034); however, this difference did not reach statistical significance in multivariate analysis that included age, 2022 ELN risk classification, and allogeneic HCT status (hazard ratio =1.00; 95% confidence interval: 0.53-1.86; P =0.989) ( Online Supplementary Figure S2 ).

Patients operated at high-volume center were more likely to have received neoadjuvant chemotherapy (21.6% versus 8.9%, p = 0.015) and showed a trend for having undergone more frequently RAMPS (51.0% versus 36.0%, p = 0.034).

While transfection with Snail-1 specific siRNA showed a trend toward downregulating vimentin expression in HEC-1A cells following treatment with 60 pmol/mL, this effect did reach statistical significance ( P = 0.034) ( Figure 6b ).

The altered group again showed a trend toward reduced DFS, although the median survival could not be calculated due to limited events (p = 0.0345, q = 0.0345).

DRGs treated with human bevacizumab + FUS (nDRGs = 12; voxel: 98.2 ± 43.7; diameter: 0.86 ± 0.14 mm) showed a trend to being smaller ( p = 0.035) than those receiving human bevacizumab alone (nDRGs = 24; voxel: 144.8 ± 72.1; diameter: 1.02 ± 0.17 mm).

The comparison between II1 and II2 showed a trend towards significance (raw p = 0.035), but this difference did not remain significant after Holm adjustment (p adj = 0.070).